Akrovis Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.50 M
- Company Age 2 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 3.46 M
About Akrovis Pharmaceuticals
Akrovis Pharmaceuticals Private Limited (APPL) is a Private Limited Indian Non-Government Company incorporated in India on 31 August 2022 (Two years and five months 24 days old ). Its registered office is in Delhi, India.
The Company is engaged in the Trading Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.50 M.
The company currently has active open charges totaling ₹3.46 M.
Krishan Yadav, Vinod Ojha, Varun Gupta, and Two other members serve as directors at the Company.
Company Details
- Location
Delhi, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U51909DL2022PTC403992
- Company No.
403992
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
31 Aug 2022
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Akrovis Pharmaceuticals?
Board Members (5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Krishan Yadav  | Director | 31-Aug-2022 | Current |
| Vinod Ojha | Director | 31-Aug-2022 | Current |
| Varun Gupta | Director | 31-Aug-2022 | Current |
| Sandeep Singh | Director | 07-Nov-2022 | Current |
| Yogesh Yadav | Director | 07-Nov-2022 | Current |
Financial Performance of Akrovis Pharmaceuticals.
Enhance accessibility to Akrovis Pharmaceuticals's financial data by unlocking access to both Standalone and Consolidated balance sheets, Profit & Loss Statements, Ratios, Related Party Transactions, and additional relevant information.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Akrovis Pharmaceuticals?
Unlock access to Akrovis Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
₹3.46 M
₹0
Charges Breakdown by Lending Institutions
- Hdfc Bank Limited : 0.35 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 25 Jun 2024 | Hdfc Bank Limited | ₹0.85 M | Open |
| 29 Jan 2024 | Hdfc Bank Limited | ₹0.91 M | Open |
| 17 Nov 2023 | Hdfc Bank Limited | ₹0.91 M | Open |
| 29 Mar 2023 | Hdfc Bank Limited | ₹0.80 M | Open |
How Many Employees Work at Akrovis Pharmaceuticals?
Unlock and access historical data on people associated with Akrovis Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Akrovis Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Akrovis Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.